You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Digestive tract conditions
  5. Inflammatory bowel disease

Vedolizumab for treating moderately to severely active ulcerative colitis

  • Technology appraisal guidance
  • Reference number: TA342
  • Published:  05 June 2015
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: Evaluation report part 2

Table of contents:
Evaluation report part 2 (pdf file)

03 - NICE request to the manufacturer for clarification on their submission

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]:  Evaluation report part 2 Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: Evaluation report part 2
26 November 2014
(5.23 Mb 26 mins )

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 25 November 2014

Back to top